WO2019099454A3 - Bibliothèques d'anticorps hautement fonctionnelles - Google Patents

Bibliothèques d'anticorps hautement fonctionnelles Download PDF

Info

Publication number
WO2019099454A3
WO2019099454A3 PCT/US2018/060933 US2018060933W WO2019099454A3 WO 2019099454 A3 WO2019099454 A3 WO 2019099454A3 US 2018060933 W US2018060933 W US 2018060933W WO 2019099454 A3 WO2019099454 A3 WO 2019099454A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibody libraries
highly functional
functional antibody
library
developability
Prior art date
Application number
PCT/US2018/060933
Other languages
English (en)
Other versions
WO2019099454A2 (fr
Inventor
Philippe Valadon
Juan Carlos Almagro
Original Assignee
Philippe Valadon
Juan Carlos Almagro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philippe Valadon, Juan Carlos Almagro filed Critical Philippe Valadon
Publication of WO2019099454A2 publication Critical patent/WO2019099454A2/fr
Publication of WO2019099454A3 publication Critical patent/WO2019099454A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne un procédé de génération de bibliothèques d'anticorps présentant une fonctionnalité améliorée et des utilisations de celles-ci par combinaison d'une bibliothèque d'anticorps présélectionné pour des propriétés fonctionnelles pertinentes pour l'aptitude au développement, comme par exemple une stabilité thermique améliorée, avec une bibliothèque de fragments CDR-H3.
PCT/US2018/060933 2017-11-15 2018-11-14 Bibliothèques d'anticorps hautement fonctionnelles WO2019099454A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762586800P 2017-11-15 2017-11-15
US62/586,800 2017-11-15

Publications (2)

Publication Number Publication Date
WO2019099454A2 WO2019099454A2 (fr) 2019-05-23
WO2019099454A3 true WO2019099454A3 (fr) 2019-07-04

Family

ID=65409453

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/060933 WO2019099454A2 (fr) 2017-11-15 2018-11-14 Bibliothèques d'anticorps hautement fonctionnelles

Country Status (1)

Country Link
WO (1) WO2019099454A2 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007056441A2 (fr) * 2005-11-07 2007-05-18 Genentech, Inc. Polypeptides de liaison comprenant des sequences diversifiees et des sequences consensus hypervariables vh/vl
WO2007134050A2 (fr) * 2006-05-09 2007-11-22 Genentech, Inc. Polypeptides de liaison à squelettes optimisés
WO2009036379A2 (fr) * 2007-09-14 2009-03-19 Adimab, Inc. Bibliothèques d'anticorps synthétiques rationnelles et leurs utilisations
WO2009132287A2 (fr) * 2008-04-24 2009-10-29 Dyax Corp. Bibliothèques de matériels génétiques comprenant de nouvelles conceptions cdr1, cdr2 et cdr3 hc et de nouvelles conceptions cdr1, cdr2 et cdr3 lc
EP2728000A1 (fr) * 2011-06-03 2014-05-07 National Institute of Advanced Industrial Science And Technology Protéine mutante de protéine a ayant une affinité réduite dans la région acide, et agent de capture d'anticorps

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7264963B1 (en) 1995-08-18 2007-09-04 Morphosys Ag Protein(poly)peptide libraries
WO2009085462A1 (fr) 2007-12-19 2009-07-09 Centocor, Inc. Conception et génération de banques d'exposition sur phage humain pix de novo au moyen d'une fusion vers pix ou pvii, vecteur, anticorps et procédés
DK2488867T3 (da) 2009-10-14 2020-11-09 Janssen Biotech Inc Fremgangsmåder til affinitetsmodning af antistoffer
SG10201509257VA (en) 2010-11-19 2015-12-30 Morphosys Ag A collection and methods for its use
US8777044B1 (en) 2012-03-16 2014-07-15 Tommy Raymus Beverage container device

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007056441A2 (fr) * 2005-11-07 2007-05-18 Genentech, Inc. Polypeptides de liaison comprenant des sequences diversifiees et des sequences consensus hypervariables vh/vl
WO2007134050A2 (fr) * 2006-05-09 2007-11-22 Genentech, Inc. Polypeptides de liaison à squelettes optimisés
WO2009036379A2 (fr) * 2007-09-14 2009-03-19 Adimab, Inc. Bibliothèques d'anticorps synthétiques rationnelles et leurs utilisations
WO2009132287A2 (fr) * 2008-04-24 2009-10-29 Dyax Corp. Bibliothèques de matériels génétiques comprenant de nouvelles conceptions cdr1, cdr2 et cdr3 hc et de nouvelles conceptions cdr1, cdr2 et cdr3 lc
EP2728000A1 (fr) * 2011-06-03 2014-05-07 National Institute of Advanced Industrial Science And Technology Protéine mutante de protéine a ayant une affinité réduite dans la région acide, et agent de capture d'anticorps

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DAE YOUNG KIM ET AL: "Antibody light chain variable domains and their biophysically improved versions for human immunotherapy", MABS, vol. 6, no. 1, 20 January 2014 (2014-01-20), US, pages 219 - 235, XP055394573, ISSN: 1942-0870, DOI: 10.4161/mabs.26844 *
LAKHRIF ZINEB ET AL: "A method to confer Protein L binding ability to any antibody fragment.", MABS 2016, vol. 8, no. 2, 2016, pages 379 - 388, XP002791446, ISSN: 1942-0870 *
NELSON RENAE S ET AL: "A universal phage display system for the seamless construction of Fab libraries", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 450, 26 July 2017 (2017-07-26), pages 41 - 49, XP085187524, ISSN: 0022-1759, DOI: 10.1016/J.JIM.2017.07.011 *

Also Published As

Publication number Publication date
WO2019099454A2 (fr) 2019-05-23

Similar Documents

Publication Publication Date Title
PH12019502283A1 (en) Anti-lag3 antibodies
EP4257613A3 (fr) Anticorps inhibiteurs de points de contrôle bispécifiques
MX2022014463A (es) Construcciones de union a antigeno para moleculas diana.
WO2020039321A3 (fr) Anticorps anti-gdf15, compositions et procédés d'utilisation
MX2018013038A (es) Anticuerpos anti-il-33, composiciones, metodos y usos de los mismos.
MX2019008146A (es) Virus alterado.
MY198059A (en) Anti-ox40 antibodies and their uses
EP4223874A3 (fr) Anticorps monoclonal humain neutralisant anti-il-33
CU24533B1 (es) Anticuerpos o fragmentos de los mismos que se unen a linfopoyetina estromal tímica (tslp) y composiciones farmacéuticas de los mismos
AU2016320748A8 (en) Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies
BR112018006350A2 (pt) anticorpos, polinucleotídeo, vetor, célula hospedeira, método para produzir o anticorpo, formulação farmacêutica e uso do anticorpo
EA201792589A1 (ru) Антитела против cd123 и конъюгаты указанных антител
WO2020051333A8 (fr) Anticorps anti-avb8, compositions et utilisations associées
MX2018015272A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
MX2018015268A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
MX2019000271A (es) Anticuerpos humanizados que transmigran a traves de la barrera hematoencefalica y usos de los mismos.
WO2018194496A3 (fr) Anticorps monoclonal à pd-l1
MX2018015274A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
EP4079760A3 (fr) Anticorps contre les toxines de clostridium difficile et leurs procédés d'utilisation
MX2019008241A (es) Un enlazador polipeptídico para preparar anticuerpos multispecíficos.
WO2015006337A3 (fr) Compositions et procédés permettant d'augmenter la demi-vie d'une protéine dans un sérum
MX2021008621A (es) Anticuerpos de inmunoglobulina a y metodos de produccion y uso.
MX2023009584A (es) Anticuerpos monoclonales anti-chinches y metodos de elaboracion y usos de los mismos.
WO2020128870A3 (fr) Procédés de production d'anticorps hétérodimères
WO2018138681A9 (fr) Anticorps spécifiques de l'hémagglutinine et leurs utilisations

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18847161

Country of ref document: EP

Kind code of ref document: A2